Background/Aims: Transarterial chemoembolization (TACE) has long been used as a palliative therapy for unresectable hepatocellular carcinoma (HCC). High-dose hepatic arterial infusion chemotherapy (HAIC) has showed favorable outcomes in patients with intractable, advanced HCC. The aim of this study was to compare the effectiveness and safety of high-dose HAIC and conventional TACE using doxorubicin for advanced HCC. Methods: The high-dose HAIC group comprised 36 patients who were enrolled prospectively from six institutions. The enrollment criteria were good liver function, main portal vein invasion (including vascular shunt), infiltrative type, bilobar involvement, and/or refractory to prior conventional treatment (TACE, radiofrequency ablation, or percutaneous ethanol injection), and documented progressive disease. Patients received 5-fluorouracil (500 mg/m 2 on days 1~3) and cisplatin (60 mg/m 2 on day 2 every 4 weeks) via an implantable port system. In the TACE group, 31 patients with characteristics similar to those in the high-dose HAIC group were recruited retrospectively from a single center. 
INTRODUCTION
Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide. 1 While treatment options including surgical resection, transplantation, and ablation can increase the chance of achieving complete remission, these strategies are not suitable for most HCC patients due to underlying cirrhosis or the advanced stage of the disease at the time of diagnosis. Still, many patients are diagnosed at an unresectable, advanced stage, though diagnosis of HCC at an early stage has been increased by virtue of surveillance of populations at high risk for the development of HCC. 2 The prognosis of patients with unresectable HCC is poor; if left untreated, the median survival is less than 6 months. 3, 4 Transarterial chemotherapy with or without embolization is widely used as a palliative therapy for unresectable, advanced HCC. Few studies have reported on patients with massive HCC (i.e., >10 cm in diameter); most reports on the treatment response of unresectable, advanced HCC have analyzed tumors 5~7 cm in size. 5, 6 Currently, repetitive hepatic arterial infusion chemotherapy (HAIC) with chemotherapeutic agents delivered via an implantable port system has been reported to be a beneficial therapeutic option for patients with advanced HCC. 
Treatment methods
In the HAIC group, the regimen consisted of 5-fluorouracil Tumor responses were classified according to the World cumulative survival rates were estimated using the Kaplan-Meier method, and the differences were compared using the log-rank test. A Cox proportional-hazards model was used to identify independent predictors of survival. A P-value less than 0.05 was considered significant. All data was analyzed using SPSS version 14.0 software (SPSS, Chicago, IL, USA).
RESULTS

Patient characteristics
A total of 67 patients were analyzed. Of these, 31 patients were included in the TACE group, and 36 in the HAIC group.
The baseline characteristics of the patients between two groups are summarized in 
Survival and prognostic factors
Median follow-up period was 125.5 days (range, 9~716 days).
The median OS of 193 days (95% CI 133~252 days) in the HAIC group was longer than that of 119 days (95% CI 41.9~196 days)
in the TACE group (P=0.026) (Fig. 1) . Univariate analysis identified prognostic factors related to survival: age (P =0.037),
Child-Pugh class (P=0.040), treatment group (P=0.026), and number of treatments (P=0.003). Of these, no factor was revealed as an independent factor for survival on multivariate analysis (Table 3) .
Adverse events
Fever, abdominal discomfort, and nausea were common.
Gastrointestinal/hepatic symptoms and neutropenia/thrombocytopenia were the most serious. Neutropenia and thrombocytopenia were more common in the HAIC group, while the frequency of hepatitis and hyperbilirubinemia was significantly higher in the TACE group (Table 4) . Most adverse events were controlled by medical treatment or dose modification of chemotherapeutic agents. However, four patients in the HAIC group and 18 in the TACE group had stopped further treatments due to progressive deterioration of liver function.
DISCUSSION
The treatment strategies for patients with intractable, advanced HCC including main portal vein invasion, diffuse bilobar involvement, or progressive tumor refractory to surgical resection or nonsurgical intervention are very limited. When hepatic function is preserved, conventional TACE using doxorubicin is commonly used as a palliative treatment for patients with unresectable, advanced HCC. 6, 16 Recently, HAIC using an implantable port system has been reported to be a useful palliative treatment for patients with advanced HCC. [7] [8] [9] [10] [11] [12] The present study was conducted to compare the efficacy and safety of high dose HAIC, which showed favorable tumor response and survival with that of conventional TACE that is widely used palliatively. In the HAIC group, the objective response rate (CR+PR) was significantly improved compared to the TACE Therefore, treatment response and OS of the TACE group in this study were poorer than in previous reports. 6, 17 In the TACE group, only single session of TACE was performed in 18 patients as a result of hepatic dysfunction as the consequence of disease progression (8 patients) or toxicity due to chemotherapeutic agents (10 patients). This might lower the effectiveness of the TACE. Moreover, the prognosis is poor in hepatitis B virus (HBV)-associated HCC. 18 HBV, the major cause of HCC in this study, might contribute to the poor OS than previously reported. 6, 18 Concerning adverse events, neutropenia and thrombocytopenia were more likely to occur in the HAIC group, although their occurrence was not statistically significant. A possible explanation is toxicity of chemotherapeutic agents as a consequence of frequent treatment cycle (4 weeks) and more treatments in the HAIC group. Hepatitis and hyperbilirubinemia were significantly frequent in the TACE group of patients.
Tumor progression in the HAIC group was less common than in the TACE group owing to a greater number of treatments, absence of embolization and good treatment response. Furthermore, high-dose chemotherapeutic agents are given over 3 days, therefore, patients might tolerate the treatment with little hepatic toxicity, making more treatments possible.
The limitation of the current study is that a randomized and prospective comparison was not made. Therefore, the disparity in terms of tumor stage, antiviral treatments, and Child-Pugh class was apparent between the two groups. However, these factors did not independently influence OS on multivariate was not an independent predictive factor for OS. This might be caused by the baseline distinction between two groups. However, it is meaningful that treatment response in the HAIC group was better than the TACE group in spite of more patients with advanced stage while preserved hepatic function and antiviral treatments.
To date, there are no standard guidelines for treatment of intractable, advanced HCC, although various therapeutic approaches for these patients have been attempted. In conclusion, high dose HAIC might be effective and safe compared to conventional TACE using doxorubicin in intractable, advanced HCC, and has a potential to improve survival outcome.
Further prospective, comparative randomized controlled trials are needed to confirm the beneficial effect of high dose HAIC in intractable, advanced HCC.
